Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
- August 14th, 2023
- 173 views
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' projected revenue of $95.45 million.
$SCYX was trading at $2.94 in after-hours, up $0.14 (+5.00%).
In contrast, Nogin, Inc. (Nasdaq: NOGN), a company in the financial sector, reported a Q2 2023 loss of $(1.13) per share, missing the consensus estimate loss of $(0.90) per share. Moreover, the company generated quarterly sales of $12.70 million, falling short of analysts' expected revenue of $14.94 million.
For the full year 2023, Nogin anticipates net revenue to range between $50 million and $55 million, attributed to the decision to exit low-margin relationships, in comparison to the consensus estimate of $79.24 million in revenue for the period.
In after-hours, $NOGN was trading at $0.80, down $0.18 (-17.95%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login